Analogs of NIH Molecular Probe ML283 Are Potent SARS-CoV-2 Helicase Inhibitors
ACS Chemical Biology · 21.02.2025 · 20 (2) · 281-296
DOI: 10.1021/acschembio.4c00458 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, online erschienen am 06.02.2025. Verfasst von David N Frick und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry & Biochemistry, The University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53217, United States. Hauptthemen laut MEDLINE: SARS-CoV-2, RNA Helicases, Antiviral Agents, Viral Nonstructural Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Division of Civil, Mechanical and Manufacturing Innovation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry & Biochemistry, The University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53217, United States.
ORCID-Profile: David N Frick, Wilfred T Tysoe
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- Division of Civil, Mechanical and Manufacturing Innovation
Zitieren
APA
Frick, D. N., Bavisotto, R. V., Hopper, N. C., & Tysoe, W. T. (2025). Analogs of NIH Molecular Probe ML283 Are Potent SARS-CoV-2 Helicase Inhibitors. ACS Chemical Biology, 20(2), 281-296. https://doi.org/10.1021/acschembio.4c00458
Vancouver
Frick DN, Bavisotto RV, Hopper NC, Tysoe WT. Analogs of NIH Molecular Probe ML283 Are Potent SARS-CoV-2 Helicase Inhibitors. ACS Chemical Biology. 2025;20(2):281-296. doi:10.1021/acschembio.4c00458
BibTeX
@article{Frick2025,
author = {Frick, David N and Bavisotto, Robert V and Hopper, Nicholas C and Tysoe, Wilfred T},
title = {Analogs of NIH Molecular Probe ML283 Are Potent SARS-CoV-2 Helicase Inhibitors},
journal = {ACS Chemical Biology},
year = {2025},
volume = {20},
number = {2},
pages = {281--296},
doi = {10.1021/acschembio.4c00458}
}
EUVIMED